Botissdental

Executive Summary

Botissdental, a privately held German biotechnology company founded in 2008 and headquartered in Berlin, specializes in developing, manufacturing, and distributing biomaterials and regenerative solutions for dental and oral surgery. The company focuses on advanced products for bone and tissue regeneration, targeting improved clinical outcomes in implantology and periodontology. With a strong emphasis on R&D, Botissdental has established a portfolio of proprietary biomaterials that address key challenges in oral surgery, such as bone defects and soft tissue healing. Operating in the high-growth dental biologics market, the company serves dental professionals across Europe and is expanding its international presence. The dental biomaterials market is driven by increasing demand for minimally invasive procedures, aging populations, and rising prevalence of dental disorders. Botissdental differentiates itself through science-backed products that enhance osseointegration and tissue regeneration. However, as a private company, financial transparency is limited, and growth depends on successful commercialization and regulatory advancements. The company faces competition from larger players like Geistlich and Dentsply Sirona, but its niche specialization in regenerative solutions provides a moat. With a solid foundation and potential for new product approvals, Botissdental is poised for steady growth, though near-term catalysts are moderate in visibility.

Upcoming Catalysts (preview)

• H2 2026Launch of next-generation bone graft substitute70% success
• 2027FDA 510(k) clearance for a soft tissue regeneration membrane50% success
• Q4 2026Strategic distribution partnership in North America60% success